GT200500367A - Derivados novedosos pirrolidilo de compuestos heteroaromaticos - Google Patents

Derivados novedosos pirrolidilo de compuestos heteroaromaticos

Info

Publication number
GT200500367A
GT200500367A GT200500367A GT200500367A GT200500367A GT 200500367 A GT200500367 A GT 200500367A GT 200500367 A GT200500367 A GT 200500367A GT 200500367 A GT200500367 A GT 200500367A GT 200500367 A GT200500367 A GT 200500367A
Authority
GT
Guatemala
Prior art keywords
compounds
pirrolidile
refers
novedous
derivatives
Prior art date
Application number
GT200500367A
Other languages
English (en)
Inventor
Thomas Allen Chappie
John Michael Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GT200500367A publication Critical patent/GT200500367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCIÓN SE REFIERE A NUEVOS DERIVADOS PIRROLIDILO DE COMPUESTOS HETEROAROMATICOS AZA BENZO CONDENSADOS QUE SIRVEN COMO INHIBIDORES EFICACES DE LAS FOSFODIESTERASA (PDE). LA INVENCIÓN TAMBIÉN SE REFIERE A COMPUESTOS QUE SON INHIBIDORES SELECTIVOS DE LA PDE10. LA INVENCIÓN SE REFIERE ADICIONALMENTE A INTERMEDIARIOS PARA LA PREPARACIÓN DE TALES COMPUESTOS; Y EL USO DE TALES COMPUESTOS EN PROCEDIMIENTOS PARA TRATAR CIERTOS TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL (SNC) U OTROS. LA INVENCIÓN SE REFIERE TAMBIÉN A PROCEDIMIENTOS PARA TRASTORNOS NEURODEGENERATIVOS Y PSIQUIATRICOS, POR EJEMPLO PSICOSIS Y TRASTORNOS QUE COMPRENDEN CONGNICIÓN DEFICIENTE COMO UN SÍNTOMA.
GT200500367A 2004-12-31 2005-12-15 Derivados novedosos pirrolidilo de compuestos heteroaromaticos GT200500367A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64040504P 2004-12-31 2004-12-31

Publications (1)

Publication Number Publication Date
GT200500367A true GT200500367A (es) 2006-08-16

Family

ID=36046318

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500367A GT200500367A (es) 2004-12-31 2005-12-15 Derivados novedosos pirrolidilo de compuestos heteroaromaticos

Country Status (23)

Country Link
US (1) US20060183763A1 (es)
EP (1) EP1838702A1 (es)
JP (1) JP2008526726A (es)
KR (1) KR20070086841A (es)
CN (1) CN101087778A (es)
AP (1) AP2007004004A0 (es)
AR (1) AR055298A1 (es)
AU (1) AU2005321015A1 (es)
BR (1) BRPI0519760A2 (es)
CA (1) CA2594251A1 (es)
CR (1) CR9135A (es)
EA (1) EA200701118A1 (es)
GT (1) GT200500367A (es)
IL (1) IL183188A0 (es)
MA (1) MA29119B1 (es)
MX (1) MX2007006301A (es)
NL (1) NL1030819C2 (es)
NO (1) NO20073958L (es)
PE (1) PE20060775A1 (es)
TN (1) TNSN07248A1 (es)
TW (1) TW200637851A (es)
UY (1) UY29317A1 (es)
WO (1) WO2006070284A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010572A (es) * 2005-03-01 2007-10-04 Wyeth Corp Compuestos de cinolina y su uso como moduladores de receptor x de higado.
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
EP1981868A2 (en) * 2006-01-27 2008-10-22 Pfizer Products Inc. Aminophthalazine derivative compounds
JP2009527562A (ja) * 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
US20070265256A1 (en) * 2006-02-21 2007-11-15 Arrington Mark P Phosphodiesterase 10 inhibitors
EP1991531A1 (en) * 2006-02-28 2008-11-19 Amgen Inc. Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
AU2007223801A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
DK2182950T3 (da) 2007-05-17 2017-11-06 Helperby Therapeutics Ltd Anvendelse af 4-(pyrrolidin-1-yl)quinolinforbindelser til at dræbe klinisk latente mikroorganismer
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI396689B (zh) * 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
US20120115849A1 (en) * 2010-11-08 2012-05-10 Demopulos Gregory A Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CA2871151C (en) * 2012-05-07 2019-03-26 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
KR101835401B1 (ko) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 키랄 핵산 어쥬번트
KR20220139425A (ko) 2012-07-13 2022-10-14 웨이브 라이프 사이언시스 리미티드 키랄 제어
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
ITVI20130032A1 (it) * 2013-02-14 2014-08-15 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di n-boc-pirrolidinone
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
TW201611834A (en) * 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
ES2776359T3 (es) * 2014-04-04 2020-07-30 H Lundbeck As Quinazolin-thf-aminas halogenadas como inhibidores de PDE1
WO2016116900A1 (en) * 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
SG11201900349VA (en) 2016-07-14 2019-02-27 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用
AU2018393409A1 (en) * 2017-12-26 2020-08-13 Mediconns (Shanghai) Biopharmaceutical Co., Ltd Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
US11266641B1 (en) 2020-09-09 2022-03-08 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
CN115417802A (zh) * 2021-05-16 2022-12-02 上海鼎雅药物化学科技有限公司 乌帕替尼及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JP3919272B2 (ja) * 1996-12-18 2007-05-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン系化合物
ES2226427T3 (es) * 1998-08-25 2005-03-16 Ortho-Mcneil Pharmaceutical, Inc. Esteres y tioeteres de piridillo como agonistas de receptor de acetilcolina nicotinico y aplicacion terapeutica.
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
KR100621287B1 (ko) * 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
US20070021404A1 (en) * 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2568929A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions

Also Published As

Publication number Publication date
AU2005321015A1 (en) 2006-07-06
KR20070086841A (ko) 2007-08-27
TW200637851A (en) 2006-11-01
WO2006070284A1 (en) 2006-07-06
CA2594251A1 (en) 2006-07-06
NL1030819C2 (nl) 2007-01-04
MA29119B1 (fr) 2007-12-03
PE20060775A1 (es) 2006-09-01
UY29317A1 (es) 2006-07-31
EP1838702A1 (en) 2007-10-03
CR9135A (es) 2007-08-14
EA200701118A1 (ru) 2007-12-28
TNSN07248A1 (fr) 2008-11-21
NL1030819A1 (nl) 2006-07-03
AR055298A1 (es) 2007-08-15
JP2008526726A (ja) 2008-07-24
CN101087778A (zh) 2007-12-12
IL183188A0 (en) 2007-08-19
BRPI0519760A2 (pt) 2009-03-10
AP2007004004A0 (en) 2007-06-30
NO20073958L (no) 2007-09-27
MX2007006301A (es) 2007-06-15
US20060183763A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
GT200500367A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
UY28750A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
SV2008002365A (es) Compuestos de quinolina heteroaromaticos ref. pc32593a
UY30080A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
GT200500198A (es) Nuevos derivados piperidilo de quinazolina e isoquinazolina
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
GT200800265A (es) Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.
WO2007129183A3 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
MX370000B (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3.
CO6321286A2 (es) Compuestos heterociclicos que contienen atomos de nitrogeno como unicos hetero atomos en el anillo en el sistema orto-condensado, y composiciones de los mismos, utiles como inhibidores de quinasa
DK1377586T3 (da) Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister
EA201791369A1 (ru) Твердые формы конденсированных гетероароматических пирролидинонов
WO2008020302A3 (en) Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
GT201200180A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
WO2008001182A8 (en) Tricyclic heteroaryl compounds as pde10 inhibitors
NI201400014A (es) Inhibidores de pde10 de pirimidina
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
PE20181008A1 (es) Compuesto piranodipiridinico
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie
PA8653001A1 (es) Azanbenzoxazoles para el tratamiento de los trastornos del snc
DOP2005000273A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
DOP2007000001A (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
UY29052A1 (es) Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central
DOP2006000004A (es) Compuestos de quinolina heteroaromaticos.